Here are the 10-K annual reports from Harrow, Inc. 11.875% Senior Notes due 2027 (HROWM) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow HROWM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HROWM filings page.
Harrow, Inc. outlines its position as a North American leader in ophthalmic disease management, combining branded pharmaceuticals with its ImprimisRx compounding business. The company markets numerous FDA-approved eye products and is building a late-stage pipeline, highlighted by MELT-300 for non‑IV, non‑opioid sublingual procedural sedation.
MELT-300 has completed Phase 3 under a Special Protocol Assessment, with an NDA planned for the first half of 2027 and a targeted U.S. launch in the second half of 2028. Harrow also plans mid‑2026 and mid‑2027 launches for BYOOVIZ and OPUVIZ biosimilars and BYQLOVI for post‑operative inflammation.
In November 2025, Harrow acquired the remaining equity of Melt Pharmaceuticals for an initial $4.3 million cash payment plus potential milestone-based cash and equity tied to MELT‑300 approval, reimbursement, and sales. Research and development expenses rose to $20.94 million in 2025 from $12.23 million in 2024 and $6.652 million in 2023, reflecting increased investment in pipeline assets and the Melt acquisition.
The company reports two segments—Branded and ImprimisRx—both U.S.-based, and had 373 employees as of February 25, 2026. Harrow emphasizes regulatory and reimbursement complexity, competition from larger pharmaceutical and biosimilar players, and evolving federal and state pharmacy rules, especially around its 503A/503B compounding facilities, as key risks to growth and profitability.